drugset / Trial / NCT00580372
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This experimental study evaluates the effects of a series of intensive drug regimens as initial treatment for Multiple Myeloma followed by 2 bone marrow transplantations 4-6 months apart in support of high-dose Melphalan, followed by Interferon treatment indefinitely.
Timeline
- Start
- 2002-08
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 1.2 g | — |
| Subject | Cytarabine | Small molecule | 1 g | — |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Doxorubicin | Other / unclassified | 10 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Vincristine | Small molecule | 0.5 mg | — |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 3e+06 iu | Subcutaneous |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 3.6 g | — |